HANGZHOU, China, Feb. 1, 2018 /PRNewswire/ -- On January 19, 2018, the global first clinical case of MitralStitch™ mitral valve repair system was completed at Yunnan Fuwai Hospital, China. This operation was jointly performed by the team of Professor Pan Xiangbin and Professor Meng Xu from Beijing Anzhen Hospital under the guidance of Academician Hu Shengshou from Fuwai Hospital. The operation used the MitralStitch™ mitral valve repair system, which is independently developed by Hangzhou DeJin Medtech Co., Ltd., an affiliate company of DiNovA Medtech. This is the first clinical application of minimally invasive transcatheter mitral valve therapies device that can be simultaneously performed in edge-to-edge repair procedure and chordal repair procedure.

According to statistics, in the United States, there are 4.6 million patients with mitral regurgitation. The transcatheter interventional mitral valve technology will bring benefits to patients who cannot be treated surgically, especially those with moderate-to-severe mitral regurgitation and those with high-risk contraindication in surgery.

Currently, various mitral valve related devices have been developed around the world, but only a very limited number of them are already on the market and certified by the European CE and the US Food and Drug Administration (FDA), among which MitraClip holds the biggest market share. MitralStitch™, developed by a team consisted of experts from Dejin Medtech, Bejing Fuwai Hospital and Beijing Anzhen Hospital, is the first device in the world that can repair both the degenerative mitral regurgitation (DMR) and the functional mitral regurgitation (FMR).

During the operation, the elderly patient who received the treatment was diagnosed as mitral valve prolapse with severe mitral regurgitation and medium tricuspid regurgitation. A small incision width 3-4cm was made between ribs of patient, and MitralStitch™ mitral valve repair system accessed the left ventricle through the apex of heart. Under the guidance of transesophageal ultrasound, apparatus forceps was operated to clamp prolapsed posterior leaflet of mitral valve and implant artificial chordae tendineae. The operation lasted for 25 minutes, from the introduction of MitralStitch™ to the implantation of artificial chordae tendineae. The degree of mitral valve regurgitation reduced to mild after operation, and the reflux area decreased from 11.3 cm2 to 1.3 cm2. The ultrasound reexamination before discharge showed that the degree of regurgitation decreased to a very small amount and the patient's mitral valve function was normal. The patient's symptoms were improved significantly.

Cardiology Homepage